In SJS/TEN management, which agent is typically considered second-line for patients intolerant of IVIG?

In SJS/TEN management, which agent is typically considered second-line for patients intolerant of IVIG?

• A. IVIG
• B. Thalidomide
• C. Cyclosporine
• D. Systemic steroids

Answer: (C)

In managing SJS/TEN, once the disease process is triggered, the goal is to halt ongoing keratinocyte death and support the patient through intensive care. If IVIG cannot be given due to intolerance or contraindication, cyclosporine is a preferred second-line option because it directly dampens the immune response driving skin damage. Cyclosporine is a calcineurin inhibitor that reduces T-cell activation and lowers the expression of Fas ligand, which is a key mediator of keratinocyte apoptosis in these conditions. By interrupting this immune cascade, it can slow or stop the progression of skin involvement and promote faster healing, and multiple studies have suggested a mortality benefit with its use in SJS/TEN. In practice, it is used at a moderate to high dose with careful monitoring for nephrotoxicity, hypertension, and drug interactions, especially with other medications common in the critically ill patient. While systemic steroids and thalidomide have been used in the past, their benefits are less clear and sometimes offset by risks like infection or teratogenicity, making them less favored as reliable second-line choices. Therefore, cyclosporine stands out as the best option when IVIG cannot be administered.

In managing SJS/TEN, once the disease process is triggered, the goal is to halt ongoing keratinocyte death and support the patient through intensive care. If IVIG cannot be given due to intolerance or contraindication, cyclosporine is a preferred second-line option because it directly dampens the immune response driving skin damage. Cyclosporine is a calcineurin inhibitor that reduces T-cell activation and lowers the expression of Fas ligand, which is a key mediator of keratinocyte apoptosis in these conditions. By interrupting this immune cascade, it can slow or stop the progression of skin involvement and promote faster healing, and multiple studies have suggested a mortality benefit with its use in SJS/TEN.

In practice, it is used at a moderate to high dose with careful monitoring for nephrotoxicity, hypertension, and drug interactions, especially with other medications common in the critically ill patient. While systemic steroids and thalidomide have been used in the past, their benefits are less clear and sometimes offset by risks like infection or teratogenicity, making them less favored as reliable second-line choices. Therefore, cyclosporine stands out as the best option when IVIG cannot be administered.